UroGen’s ZUSDURI Surge Meets a Costly Pipeline Buildout
ZUSDURI sales are climbing fast, but cash burn, debt and new development plans complicate the case for self-funded growth.
Makkler Newsroom · Sep 23, 05:57 PM · 2 min read
Market open· · USD · Data may be delayed
Avg. target $60.71 (+115.1%)
Prices may be delayed and are for informational purposes only - not investment advice.
Profitability and valuation from the filed statements
Answers from price, statements, peer and news data. Not investment advice.
MakklerAI Q&A is open to MakklerPRO members. Upgrade to MakklerPRO